Your browser doesn't support javascript.
loading
A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system.
Lee, Shwu-Maan; Hickey, John M; Miura, Kazutoyo; Joshi, Sangeeta B; Volkin, David B; King, C Richter; Plieskatt, Jordan L.
Afiliação
  • Lee SM; PATH's Malaria Vaccine Initiative (MVI), 455 Massachusetts Avenue NW, Suite 1000, Washington, DC, 20001-2621, USA. smlee@path.org.
  • Hickey JM; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, 66047, USA.
  • Miura K; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
  • Joshi SB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, 66047, USA.
  • Volkin DB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, 66047, USA.
  • King CR; PATH's Malaria Vaccine Initiative (MVI), 455 Massachusetts Avenue NW, Suite 1000, Washington, DC, 20001-2621, USA.
  • Plieskatt JL; PATH's Malaria Vaccine Initiative (MVI), 455 Massachusetts Avenue NW, Suite 1000, Washington, DC, 20001-2621, USA.
Sci Rep ; 10(1): 395, 2020 01 15.
Article em En | MEDLINE | ID: mdl-31942034
ABSTRACT
The Plasmodium falciparum gametocyte surface protein, Pfs48/45, is a potential target for malaria transmission-blocking vaccines. However, due to its size and complexity, expression of the full-length protein has been difficult, leading to focus on the C-terminal six cysteine domain (6C) with the use of fusion proteins to facilitate expression and folding. In this study, we utilized the baculovirus system to evaluate the expression of three Pfs48/45 proteins including the full-length protein, the 6C domain fragment and the 6C domain mutant to prevent glycosylation. Expression of the recombinant Pfs48/45 proteins was conducted in super Sf9 cells combined with the use of tunicamycin to prevent N-glycosylation. The proteins were then evaluated as immunogens in mice to demonstrate the induction of functionally active polyclonal antibody responses as measured in the standard membrane feeding assay (SMFA). Only the 6C protein was found to exhibit significant transmission-reducing activity. Further characterization of the biologically active 6C protein demonstrated it was homogeneous in terms of size, charge, conformation, absence of glycosylation, and containing proper disulfide bond pairings. This study presents an alternative expression system, without the need of a fusion protein partner, for the Pfs48/45 6C protein fragment including further evaluation as a potential transmission-blocking vaccine candidate.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Proteínas Recombinantes / Anticorpos Antiprotozoários / Proteínas de Protozoários / Malária Falciparum / Vacinas Antimaláricas / Antígenos de Protozoários Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Proteínas Recombinantes / Anticorpos Antiprotozoários / Proteínas de Protozoários / Malária Falciparum / Vacinas Antimaláricas / Antígenos de Protozoários Idioma: En Ano de publicação: 2020 Tipo de documento: Article